Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results

ANNAPOLIS, Md., May 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2009.

For the first quarter of 2009, PharmAthene recognized revenues of $5.5 million compared to $5.8 million in the same period of 2008. Revenues for the most recent quarter consisted primarily of contract funding from the U.S. government for the development of Protexia(R), SparVax(TM) and RypVax(TM).

Research and development expenses were $5.7 million for the quarter ended March 31, 2009 compared to $5.9 million in the same period last year. For both quarterly periods these expenses resulted from research and development activities related to programs for Valortim(R) and Protexia(R), and for the first quarter of 2009 also reflect activities related to the SparVax(TM), RypVax(TM) and our third generation rPA anthrax vaccine programs, which we acquired in the second quarter of 2008.

General and administrative expenses for the Company were $5.1 million for the quarter ended March 31, 2009 compared to $4.4 million in the same period in 2008. These amounts include non-cash stock compensation expense of $0.7 million and $0.5 million for the three months ended March 31, 2009 and 2008, respectively. General and administrative expenses increased $0.7 million in the first quarter of 2009 primarily due to increased consulting and legal services associated with compliance and operating as a publicly traded entity, costs related to preparing and submitting various bids and proposal, litigation efforts, and increased employee costs resulting primarily from the additional headcount through the Avecia acquisition. These increases were partially offset by reduced travel and other administrative overhead costs.

For the first quarter of 2009 PharmAthene's net loss attributable to common shareholders was $6.0 million or $0.23 per share, compared to $4.7 million or $0.22 per share in the same period of 2008.

PharmAthene's available cash, cash equivalents and short term investments at March 31, 2009 totaled $24.0 million, which excludes restricted cash totaling $9.0 million. For the period ended December 31, 2008, the Company's available cash, cash equivalents and short term investments were $22.9 million, excluding restricted cash of $12.0 million. The increase in cash, cash equivalents and short-term investments at March 31, 2009 from December 31, 2008 is primarily attributable to the receipt of approximately $5.0 million in net proceeds from the public offering of common stock and warrants completed in March 2009, partially offset by funding of operations and the repayment of debt.

David P. Wright, President and Chief Executive Officer of PharmAthene, noted, "The first quarter of 2009 was a productive one for PharmAthene. In addition, we have recently met with senior officials at the Biomedical Advanced Research and Development Authority (BARDA) to discuss the pending FDA submission of our comprehensive regulatory strategy for SparVax(TM) under the recently amended RFP. We submitted a copy of the plan to BARDA last week for review. BARDA officials indicated a willingness to review our proposal when received and we remain on target to meet our stated goal of submitting our plan to FDA by May 21, 2009."

Mr. Wright continued, "BARDA has recently assumed responsibility for funding and oversight of activities under our previous contract for the development of SparVax(TM) with the National Institute of Allergy and Infectious Diseases (NIAID). The scope of work under the BARDA contract, which took effect April 1, 2009, will cover ongoing stability studies, development of potency assays, as well as certain manufacturing technology transfer and scale-up activities for SparVax(TM). We continue to work closely with BARDA to ensure that development activities for SparVax(TM) proceed uninterrupted during the negotiations under the RFP."

Conference Call and Webcast Information

PharmAthene management will host a conference call to discuss the Company's first quarter results on May 15, 2009, at 10:00 a.m., E.T. The dial-in number for U.S. callers is 866-783-2137 and for international callers is 857-350-1596. The participant passcode is 47746139.

A replay of the conference call will be available beginning at approximately 1:00 p.m. Eastern Time on May 15, 2009 until approximately 11:59 p.m. Eastern Time June 30, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 34158052.

The webcast of the conference call will be available until June 15, 2009 and can be accessed from the company's website at A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

                                -- Tables Follow --

                                 PHARMATHENE, INC.

                            CONSOLIDATED BALANCE SHEETS

                                               March 31,     December 31,
                                                 2009            2008

    Current assets:
      Cash and cash equivalents               $17,245,420     $19,752,404
      Restricted cash                           9,000,000      12,000,000
      Short-term investments                    6,773,594       3,190,912
      Accounts receivable                       9,961,596       8,890,077
      Other receivables                         1,089,857       1,391,512
      Prepaid expenses and other current assets   960,939         917,125
    Total current assets                       45,031,406      46,142,030

    Long-term restricted cash                           -       1,250,000
    Property and equipment, net                 5,211,214       5,313,219
    Patents, net                                  875,098         925,489
    Other long-term assets                        223,026         220,531
    Deferred costs                                 34,643          37,092
    Goodwill                                    2,348,453       2,502,909
    Total assets                              $53,723,840     $56,391,270


    Current Liabilities:
      Accounts payable                         $3,409,022      $3,870,871
      Accrued expenses and other liabilities   12,197,532      14,624,757
      Convertible notes                        13,828,776      13,377,505
      Current portion of warrants to
       purchase common stock                      377,753               -
      Current portion of long-term debt         3,947,979       4,000,000
    Total current liabilities                  33,761,062      35,873,133

    Other long-term liabilities                 2,230,670         626,851
    Warrants to purchase common stock           1,158,031               -
    Long-term debt                                      -         928,117
    Total liabilities                          37,149,763      37,427,831

    Stockholders' equity:
      Common stock, $0.0001 par value;
       100,000,000 shares authorized;
       28,012,031 and 25,890,143 shares
       issued and outstanding at March 31,
       2009 and December 31, 2008;
       respectively,                                2,802           2,589
      Additional paid-in capital              146,662,830     142,392,163
      Accumulated other comprehensive (loss)
       income                                    (260,869)        386,351
      Accumulated deficit                    (129,830,686)   (123,817,664)
    Total stockholders' equity                 16,574,077      18,963,439
    Total liabilities and stockholders'
     equity                                   $53,723,840     $56,391,270

                                  PHARMATHENE, INC.


                                           Three months ended March 31,
                                              2009             2008

    Contract revenue                       $5,521,903       $5,819,054
    Other revenue                                   -           21,151
                                            5,521,903        5,840,205

    Operating expenses:
      Research and development              5,695,326        5,929,319
      General and administrative            5,145,999        4,357,959
      Depreciation and amortization           192,478          196,103
    Total operating expenses               11,033,803       10,483,381

    Loss from operations                   (5,511,900)      (4,643,176)
    Other income (expense):
      Interest income                         104,245          471,765
      Change in market value of warrants      123,674                -
      Other expense                          (123,841)               -
      Interest expense                       (602,115)        (666,997)
      Change in market value of derivative
       instruments                             (3,085)          89,280
    Total other income (expense)             (501,122)        (105,952)

    Net loss                              $(6,013,022)     $(4,749,128)
    Basic and diluted net loss per share       $(0.23)          $(0.22)
    Weighted average shares used in
     calculation of basic and diluted net
     loss per share                        26,009,387       22,087,121

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
(Date:12/4/2019)... Lafayette, Indiana (PRWEB) , ... December 04, 2019 ... ... improved strategy to further enhance dissolution and stabilize amorphous materials. Additionally, their PDF ... and enhance the ability to describe these compositions both in regulatory and patent ...
(Date:11/27/2019)... ... November 25, 2019 , ... Silony Medical, a medical technology ... navigated surgery in the UK. The procedure was performed in the UK’s largest ... Aftab and Dr. Alexander Montgomery. The surgery, which took place on July 22, ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and aerospace market intelligence ... generation units from 2019-2028. The value of this production is $728 million in ... worth $569 million. , Reference to 2017 is important, as that was ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... for biopharmaceutical R&D, today announced that Immatics Biotechnologies , a clinical-stage ... Biologics® to streamline their R&D operations related to the discovery and ...
Breaking Biology Technology:
(Date:12/2/2019)... , ... December 01, 2019 , ... ... and greatest tools, technologies, and techniques to hit the life-science landscape. For more ... innovative products speeding work in laboratories and facilitating biological discovery. This year’s crop ...
(Date:11/27/2019)... ... November 26, 2019 , ... Smile ... Ellyn, IL practice for Invisalign® treatment. Invisalign orthodontics uses a series ... a misaligned bite, also known as malocclusion, present both functional and cosmetic concerns. ...
(Date:11/27/2019)... ... November 27, 2019 , ... ... device, equipped with surface electromyography (sEMG) sensors that measure and display muscle activity ... the specific muscles being targeted for treatment. Both patient and therapist can see ...
Breaking Biology News(10 mins):